144 related articles for article (PubMed ID: 18220767)
1. Current and emerging therapeutic approaches in HCV-related mixed cryoglobulinemia.
Sansonno D; Tucci FA; Troiani L; Sansonno L; Dammacco F
Curr Med Chem; 2008; 15(2):117-26. PubMed ID: 18220767
[TBL] [Abstract][Full Text] [Related]
2. L11. Hepatitis C virus mixed cryoglobulinemia vasculitis: therapeutic options.
Cacoub P; Terrier B; Saadoun D
Presse Med; 2013 Apr; 42(4 Pt 2):523-7. PubMed ID: 23453499
[No Abstract] [Full Text] [Related]
3. [Current therapeutic strategies for HCV-associated cryoglobulinemia].
Iannuzzella F; Garini G
Reumatismo; 2008; 60(3):163-73. PubMed ID: 18854876
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis.
Saadoun D; Delluc A; Piette JC; Cacoub P
Curr Opin Rheumatol; 2008 Jan; 20(1):23-8. PubMed ID: 18281853
[TBL] [Abstract][Full Text] [Related]
5. How HCV has changed the approach to mixed cryoglobulinemia.
Della Rossa A; Baldini C; Tavoni A; Bombardieri S
Clin Exp Rheumatol; 2009; 27(1 Suppl 52):S115-23. PubMed ID: 19646357
[TBL] [Abstract][Full Text] [Related]
6. Long-term remission with rituximab in a patient with severe hepatitis C virus-induced mixed cryoglobulinemia.
Fortea-Ormaechea JI; Lozano-Maya M; Adán-Merino L; Barrio-Antoranz J; Martín-Chavarri S; Corchete-Prats E; Martínez-Acebes E; Aldeguer-Martínez M
Rev Esp Enferm Dig; 2013 Sep; 105(8):490-3. PubMed ID: 24274448
[TBL] [Abstract][Full Text] [Related]
7. Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.
Boglione L; Cusato J; Allegra S; Cariti G; Di Perri G; D'Avolio A
Arch Virol; 2015 Aug; 160(8):2009-17. PubMed ID: 26060059
[TBL] [Abstract][Full Text] [Related]
8. The dilemma of treating hepatitis C virus-associated cryoglobulinemia.
Roccatello D; Fenoglio R; Sciascia S
Curr Opin Rheumatol; 2019 Sep; 31(5):499-504. PubMed ID: 31090590
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.
Gragnani L; Visentini M; Fognani E; Urraro T; De Santis A; Petraccia L; Perez M; Ceccotti G; Colantuono S; Mitrevski M; Stasi C; Del Padre M; Monti M; Gianni E; Pulsoni A; Fiorilli M; Casato M; Zignego AL
Hepatology; 2016 Nov; 64(5):1473-1482. PubMed ID: 27483451
[TBL] [Abstract][Full Text] [Related]
10. Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies.
Fabrizi F; Dixit V; Messa P
J Med Virol; 2013 Jun; 85(6):1019-27. PubMed ID: 23588727
[TBL] [Abstract][Full Text] [Related]
11. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis.
Landau DA; Rosenzwajg M; Saadoun D; Trébeden-Negre H; Klatzmann D; Cacoub P
Arthritis Rheum; 2008 Sep; 58(9):2897-907. PubMed ID: 18759287
[TBL] [Abstract][Full Text] [Related]
12. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis.
Saadoun D; Resche-Rigon M; Sene D; Perard L; Karras A; Cacoub P
Ann Rheum Dis; 2008 Oct; 67(10):1431-6. PubMed ID: 18178690
[TBL] [Abstract][Full Text] [Related]
13. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response.
Landau DA; Saadoun D; Halfon P; Martinot-Peignoux M; Marcellin P; Fois E; Cacoub P
Arthritis Rheum; 2008 Feb; 58(2):604-11. PubMed ID: 18240235
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease.
Petrarca A; Rigacci L; Caini P; Colagrande S; Romagnoli P; Vizzutti F; Arena U; Giannini C; Monti M; Montalto P; Matucci-Cerinic M; Bosi A; Laffi G; Zignego AL
Blood; 2010 Jul; 116(3):335-42. PubMed ID: 20308604
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus-related cryoglobulinemia and glomerulonephritis: pathogenesis and therapeutic strategies.
Garini G; Allegri L; Vaglio A; Buzio C
Ann Ital Med Int; 2005; 20(2):71-80. PubMed ID: 16052839
[TBL] [Abstract][Full Text] [Related]
16. PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis.
Saadoun D; Resche Rigon M; Pol S; Thibault V; Blanc F; Pialoux G; Karras A; Bazin-Kara D; Cazorla C; Vittecoq D; Musset L; Peltier J; Decaux O; Ziza JM; Lambotte O; Cacoub P
J Hepatol; 2015 Jan; 62(1):24-30. PubMed ID: 25135864
[TBL] [Abstract][Full Text] [Related]
17. TLR9 signalling in HCV-associated atypical memory B cells triggers Th1 and rheumatoid factor autoantibody responses.
Comarmond C; Lorin V; Marques C; Maciejewski-Duval A; Joher N; Planchais C; Touzot M; Biard L; Hieu T; Quiniou V; Desbois AC; Rosenzwajg M; Klatzmann D; Cacoub P; Mouquet H; Saadoun D
J Hepatol; 2019 Nov; 71(5):908-919. PubMed ID: 31279905
[TBL] [Abstract][Full Text] [Related]
18. The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders.
Landau DA; Rosenzwajg M; Saadoun D; Klatzmann D; Cacoub P
Ann Rheum Dis; 2009 Mar; 68(3):337-44. PubMed ID: 18434450
[TBL] [Abstract][Full Text] [Related]
19. Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection.
Benstead TJ; Chalk CH; Parks NE
Cochrane Database Syst Rev; 2014 Dec; (12):CD010404. PubMed ID: 25525951
[TBL] [Abstract][Full Text] [Related]
20. [Hepatitis-C-virus-associated cryoglobulinemia. Pathogenesis, diagnosis and treatment].
Staak JO; Glossmann JP; Diehl V; Josting A
Med Klin (Munich); 2002 Oct; 97(10):601-8. PubMed ID: 12386793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
